RE: Osd17 Feb 2025 07:34
Couldn't be any clearer, and if we invest on AIM we have to accept , reluctantly, that funds are needed for growth, and this was for growth /investment
Physiomics has achieved a record year for the total value of contract wins and is tracking in line with expectations for the full year ending 30 June 2025. The quality and impact of the Company's solutions can be evidenced in the two recent publications, with partners Astellas Pharma Inc and Merck KGaA, but also the success of Numab Therapeutics' NM26 asset - an early clinical programme supported by Physiomics prior to being acquired by J&J for US$1.2 billion. These recent case studies will become invaluable tools in building our pipeline further and winning new business. With this latest round of funding, investment is being made in key growth initiatives across the business as we remain in active discussions with a variety of clients on several further contracts."